☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease
April 24, 2025
Personalized Medicine: A Paradigm Shift in Modern Treatment Approach
April 23, 2025
Boehringer Ingelheim Enters a ~$573M Deal with Tessellate Bio to Develop Novel Therapies for ALT-positive tumors
April 23, 2025
VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies
April 23, 2025
Regeneron Enters a ~$3B Multi-Year Manufacturing Agreement with FUJIFILM Diosynth Biotechnologies
April 23, 2025
Reuters Pharma 2025: Post-Conference Talks Featuring Hector De La Riva
April 22, 2025
Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake
April 22, 2025
Evaluating SDoH in SLE: Vijay Nadipelli from GSK in a Riveting Conversation with PharmaShots
April 21, 2025
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
Email
First Name
Last Name
Company Name
Area/Designation
Daily Newsletter
Weekly Newsletter
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
Modal title
×
Modal body text goes here.
